CRKL is a 39 kDa adapter protein, originally cloned in proximity to the BCR gene on chromosome 22, which has a key regulatory role in hematopoietic cells. CRKL has one SH2 and two SH3 domains, with 60% homology to CRK II. CRKL is a prominent substrate of the BCR/ABL oncoprotein in chronic myelogenous leukemia and binds to both BCR/ABL and c-ABL. CRKL has been shown to be tryosine phosphorylated in response to normal hematopoietic growth factor receptor signaling with ligands such as thrombopoietin, erythropoietin or steel factor. Additionally, CRKL is involved in signaling initiated by crosslinking of ␤ integrins, and B cell or T cell receptors. Structurally, the amino-terminal SH3 domain of CRKL has been shown to bind proteins such as C3G, SOS, PI3-K, c-ABL or BCR/ABL. The SH2 domain of CRKL can bind to tyrosine phosphorylated proteins such as CBL, HEF1, CAS or paxillin. This review summarizes the current knowledge on the function of this unique adapter protein in normal hematopoietic and leukemic cell signaling.
erythropoietin, 11 and steel factor. 12 Also, CRKL binds constitutively and inducibly to key molecules in cellular signaling such as in response to integrin or hematopoietic growth factor crosslinking ( Figure 2 ). In CML, CRKL is tyrosine phosphorylated and interacts directly with the transforming protein BCR/ABL. [2] [3] [4] The function of CRKL tyrosine phosphorylation in normal and leukemic cell signaling is not known. It is possible that tyrosine phosphorylation may help CRKL to function as a signaling molecule. Various interactions of CRKL occur through SH domains, and the current knowledge about the role of CRKL as it interacts with other proteins in normal and leukemic cell signaling is discussed below.
The SH3 domains of CRKL in normal cell signaling
SH3 domains are comprised of about 60 amino acids and mediated protein-protein interactions with proline-rich motifs of the general sequence PXXP (Pro-X-X-Pro; X indicates no specific amino acid). The proline-rich motifs are located in a helical structure and bind mostly through hydrophobic interactions to the SH3 binding pocket. SH3 domains recognize proline-rich helices in forward and reverse configuration. The two possible different configurations in the SH3 target protein have the consensus sequence of XpXPpXP (X-p-X-Pro-p-XPro = class I; p indicates a residue that tends to be proline) or XPpXPpX (X-Pro-p-X-Pro-p-X = class II), respectively. The two critical conserved prolines are located in two different hydrophobic pockets, in part formed by aromatic residues in the SH3 domain. 13, 14 Recently a consensus sequence for binding to the CRK SH3 domain, PXLPXK (Pro-X-Leu-Pro-X-Lys), has been described. 15, 16 It is likely that the CRKL binding domains recognize the same or similar motifs/proteins as CRK (Table 1) . Consistent with the structural and functional homology, all known CRKL SH3 binding proteins, including C3G, SOS, PI3-K and c-ABL contain this motif ( Figure 3) . Also, it has been shown that the SH3 domain of CRK proteins involved in binding other proteins is likely to be the amino-terminal SH3 domain but not the carboxy-terminal SH3 domain. 17 Described below are some proteins that are known to interact through the CRKL SH3 domain.
Figure 2
Model of CRKL in a stable complex with CBL and PI3-K after steel factor (SF) stimulation and in BCR/ABL-transformed cells. PI3-K can activate the serine kinase AKT which in turn inactivates BAD. BAD phosphorylated on serine residues can bind to 14-3-3 proteins and is thus prevented from contributing to apoptosis.
C3G, SOS
The understanding of CRKL function can be partially obtained through its binding partners. For example, in B cells and T cells CRKL is constitutively linked to the nucleotide exchange factors C3G and SOS 19, 20, 34, 35 (Figure 4 ). SOS has known guanine exchange factor activity for p21 RAS ; whereas C3G appears to have specific guanine exchange activity for p21 RAP1 . 36 C3G is a member of the SOS family with similarity to the protein tyrosine phosphatase CDC25. 37 C3G does not have substrate specificity for p21 RAS , 36 but its substrate p21 RAP1 appears to regulate, at least in part, the signal from p21 RAS to the RAF kinase. The CRKL/C3G complex has been found to be linked to tyrosine phosphorylated proteins, such as CBL in T cell signaling. 19 In anergic T cells, which have been found to have elevated levels of active p21 RAP1 , there is a constitutive complex of CRKL with C3G and CBL. 38 
PI3-K
In signaling through c-KIT, the receptor for steel factor, CRKL has been described to be directly downstream of the c-KIT/PI3-K receptor complex ( Figure 2 ). After steel factor stimulation in the megakaryoblastic MO7e cell line, CRKL was in a stable complex that contained c-KIT and PI3-K (phosphatidylinositol 3-kinase). The interaction of CRKL with the 85 kDa regulatory subunit of PI3-K was inducible. The CRKL interaction with the 85 kDa regulatory subunit was mediated via the CRKL-SH3 domain. 12 The biological effects of activated PI3-K may vary widely from cell to cell, ranging from regulation of apoptosis, viability, or early gene expression, to regulation of adhesion. [39] [40] [41] Interestingly, recent findings suggest that PI3-K activates the serine kinase AKT
Figure 3
Sequence comparison of proline-rich domains of CRKL SH3 binding proteins (proper amino acid numbers shown) with the CRK SH3 consensus binding motif.
Figure 4
CRKL is partially localized to the cytoskeleton. A model of a focal adhesion with actin fibers leading to an integrin receptor ligated with extracellular matrix proteins (ECM) is shown. The CRKL SH2 domain interacts with tyrosine phosphorylated CBL, CAS, HEF1, or paxillin, and the CRKL SH3 domain binds to C3G, SOS, or BCR/ABL. Direct interaction of CRKL with BCR/ABL contributes to transformation by this tyrosine kinase oncoprotein. which in turn phosphorylates the BCL-2-related protein BAD. [42] [43] [44] [45] If phosphorylated by AKT BAD can bind to 14-3-3 proteins and its proapoptotic potential is blocked 46 ( Figure 2 ). Thus, the CRKL/PI3-K interaction may be quite important in cell viability signaling.
ABL
The CRKL SH3 domain also binds constitutively to the tyrosine kinase c-ABL in hematopoietic and non-hematopoietic cells. 21, 22, 47 However, a function of this CRKL/c-ABL signaling complex in normal signaling has yet to be described. c-ABL has been shown to be involved in transcriptional activation, 48 is activated in response to certain types of DNA damage, 49, 51 and is mobilized in the cell in response to integrin stimulation. 51 Interestingly, in v-Crk-transformed cells, several proteins are heavily tyrosine phosphorylated, and it has been suggested that v-Crk and CRK may serve as regulatory subunits of the c-ABL tyrosine kinase. 9, 52 However, in contrast to CRK, a role of c-ABL as the CRKL tyrosine kinase in normal cells has not yet been shown.
It is not clear at this time if CRKL is a regulator of C3G, SOS, PI3-K, or c-ABL enzyme activity, or downstream effectors that require any of these enzyme activities for an as yet unknown signaling function. Nevertheless, CRKL is likely to act as an intermediate that has the function to link the enzymes to tyrosine phosphorylated proteins using the CRKL SH2 domain.
The SH2 domain of CRKL in normal cell signaling SH2 domains are conserved phosphotyrosine binding motifs of approximately 100 amino acids. The specificity of SH2 domain interactions with phosphotyrosine within a substrate/target protein is mostly given by the second or third amino acid carboxy terminal of this tyrosine residue. The conserved amino acids in the SH2 binding pocket determine the Review M Sattler and R Salgia 641 specificity for phosphotyrosine binding, which occurs through hydrogen bonds and amino-aromatic interactions. Additional amino acids in the binding pocket determine the recognition specificity of the amino acids adjacent to the phosphotyrosine. 53, 54 Also, a point mutation of arginine (R) to lysine (K) in the conserved FLVRES (Phe-Leu-Val-Arg-Glu-Ser) motif in the SH2 domain interferes with phosphotyrosine binding. 55, 56 The CRK SH2 domain binds to pYXXP (phosphoTyr-X-XPro) motifs. 57 Similarly, the CRKL SH2 domain has recently been shown to bind pYXXP motifs in the focal adhesion protein paxillin 33 and the proto-oncoprotein CBL. 58 Also, the SH2 domain of CRKL has been found to bind to HEF1, or CAS. 28, 30 It has been shown that the CRK-SH2 domain can intramolecularly bind to the tyrosine at position 221(Y 221 XXP). 61 CBL is the cellular homolog of v-Cbl, the oncoprotein in the CAS NS-1 retrovirus which induces pre-B cell lymphomas and myelogenous leukemias in mice. [62] [63] [64] In mammalian cells, the specific function of CBL is not known, but the CBL homolog Sli-1 in C. elegans is a negative regulator of the epidermal growth factor receptor tyrosine kinase homologue Let-23. 65 Also, CBL-B, a CBL homolog with 50% sequence similarity has been recently cloned, 66 and it will be interesting if this can interact with CRKL in hematopoietic cells.
CAS, HEF1
The interaction of the CRKL SH2 domain with its target proteins has been studied in integrin signaling. Ligation of ␤1 integrin receptors induces association of CRKL with CBL, HEF1, or CAS. 29, 30 CAS (for Crk-associated substrate) was cloned as a major 130 kDa tyrosine phosphorylated protein in response to v-crk transformation. 27 Currently, there are three CAS-related molecules (the 130 kDa protein CAS, the 110 kDa protein HEF1/CAS-L, 67, 68 and the 95 kDa protein SIN/EFS 69, 70 ). The structure for CAS-family members includes an amino-terminal SH3 domain, multiple YXXP motifs (substrate domain), and potential SRC-binding sites at the Cterminus. The 110 kDa protein HEF1 (for human enhancer of filamentation 1) is a tissue-specific protein first identified during cloning of human genes which induce morphological changes in S. cerevisiae. Expression of the HEF1 C-terminus induces pseudohyphae in S. cerevisiae. 67 Interestingly, in the human megakaryoblastic cell line MO7e, CRKL was induced to bind to only CBL, and in the T cell line H9 CRKL was found to bind to only HEF1 after ␤1 integrin cross-linking, even though both cell lines express HEF1 and CBL. 30 This provides for the possibility of an intracellular signaling 'switch' that could couple integrin signaling to different biological effects as related to CRKL.
Role of CRKL in chronic myelogenous leukemia
CML is caused by the Philadelphia chromosome translocation (t [9;22] ) which generates the potent oncogenic BCR/ABL tyrosine kinase. Clinically, patients with CML can have easy fatigue, abdominal complaints secondary to splenomegaly, leukocytosis, and anemia. CML is characterized by a stable phase in which there is excessive proliferation and accumulation of cell in the myeloid series. In the stable phase, the leukocyte alkaline phosphatase score is low or absent in over 90% of patients with CML. Stable phase invariably can lead to progression with an advanced leukemic phase. Typically, the median interval is 3.5-5 years for conversion from chronic to blastic phase. The prognosis of patients with blastic phase leukemia is quite poor. [71] [72] [73] There are multiple substrates for tyrosine phosphorylation in CML cells. CRKL was shown to be a prominent tyrosine phosphorylated protein in primary cells from patients with CML.
2-4 BCR/ABL is localized to the cytoskeleton and induces tyrosine phosphorylation of multiple substrates, including BCR/ABL itself, CRKL, CBL, HEF1, CAS, paxillin, and other proteins. 73 As a distinct difference to CRKL, CRK has not been shown to be tyrosine phosphorylated in BCR/ABL-transformed cells. Nevertheless, tyrosine phosphorylation of CRKL does not appear to be important for transformation by BCR/ABL since overexpression of the Y 207 to Phe CRKL mutant in myeloid cells did not effect BCR/ABL transformation. It should be also noted that phosphorylation of Y 207 in CRKL has not been found to be important for fomation of signaling complexes. 74 Overexpression of CRKL in Rat-1 fibroblasts but not hematopoietic cells can lead to transformation and activation of the RAS pathway. 47, 75 It is believed that in CML CRKL links several key molecules leading to leukemic cell growth and/or inhibition of apoptosis.
CRKL is linked to BCR/ABL in CML
BCR/ABL interacts through a proline-rich sequence within ABL directly with the CRKL SH3 domain 22, 76 ( Figure 2 ). CRKL becomes tyrosine phosphorylated by BCR/ABL on tyrosine 207 Y 207 , 74 binds with its SH2 domain to CBL and is in a multimeric complex with PI3-K, c-ABL, and BCR/ABL. 22, 26 It is likely that CRKL SH2 binding to tyrosine phosphorylated proteins also leads to activation of other pathways that could contribute to leukemic transformation. Interestingly, binding of CRKL through its SH3 to BCR/ABL appears to contribute to leukemia, since deletion of the proline-rich domain that binds CRKL in BCR/ABL reduces the ability of the oncoprotein to transform Rat-1 fibroblasts. 47 In myeloid cells BCR/ABL leads to growth factor independence. 77 Myeloid cell expressing BCR/ABL lacking the CRKL SH3 binding site are still growth factor dependent. 76 It is possible that transformation and growth factor independence in myeloid cells is a different regulated process than in fibroblasts.
Similar to normal cell signaling, the CRKL SH2 domain binds to CAS family proteins 28 and CBL, 22, 26 and the interaction of the known SH3 binding proteins C3G, SOS and ABL does not change upon BCR/ABL transformation. 20 The contri- bution of CRKL to transformation is independent from GRB2, however, the exact mechanism is unknown. 47 GRB2 is an SH2-SH3-SH3 adapter protein that contributes to BCR/ABL transformation by linking SOS, and thus the RAS-pathway, to Y 177 in BCR/ABL. 78, 79 It is possible that multiple abnormalities of several adapter proteins are required for full leukemic potential.
80
CRKL links BCR/ABL to the focal adhesion proteins paxillin and CAS BCR/ABL induces global abnormalities of cytoskeletal function, 81 alters adhesion properties to extracellular matrix components such as fibronectin, 82, 83 and alters cell motility as reflected by membrane ruffling, filipodia/lamellipodia, and cell migration. 84 Unlike c-ABL, BCR/ABL is primarily localized to the actin cytoskeleton 85 and is associated with focal adhesion proteins. 81 BCR/ABL-transformed cells have an altered F-actin structure and have tyrosine phosphorylation of focal adhesion proteins such as tensin, talin, vinculin, RAFTK, p125 FAK , and paxillin. 28, 33, 86 CRKL is the key signaling molecule which links BCR/ABL to the focal adhesion protein paxillin. 33 Paxillin is a 68 kDa multi-functional protein with three YXXP motifs at the N-terminus and four LIM domains at the C-terminus. 87 By mutational analysis, Y 31 XXP and Y 118 XXP in paxillin have been shown to bind to the CRKL SH2 domain 33 and to the CRK SH2 domain. 32, 88 The association of CRKL with cytoskeletal proteins such as paxillin could contribute significantly to leukemic transformation. Although CRK and CRKL can bind tyrosine phosphorylated paxillin, it should be noted that at least in signaling through insulin-like growth factor-I in rat uterine tissue, they appear to have different signaling properties. CRKL and CRK are pre-associated with paxillin, and after insulin-like growth factor-I stimulation, the association of paxillin with CRKL is decreased and the association with CRK is increased. 89 The SH2 domain of CRKL and CRK can also bind to tyrosine phosphorylated CAS in a similar fashion as paxillin. CAS has numerous YXXP motifs in the 'substrate domain' that are targets for tyrosine kinases, including BCR/ABL. Interestingly, CAS is constitutively associated with paxillin in normal and BCR/ABL-transformed cells. CRKL associates with CAS and paxillin in BCR/ABL-transformed cells and therefore has the potential role to recruit BCR/ABL to the cytoskeleton. 28 This physical interaction with BCR/ABL mediated through CRKL could contribute to the known defects associated with the cytoskeleton in CML cells.
Conclusions
In summary, CRKL is an adapter protein, and the CRKL SH2 domain can bind to tyrosine phosphorylated proteins, in particular CBL, CAS, HEF1 or paxillin. The CRKL SH3 domain binds to BCR/ABL, ABL, C3G, SOS, or PI3-K. CRKL is tyrosine phosphorylated by BCR/ABL and hematopoietic growth factors. However, the function of tyrosine phosphorylated CRKL has not yet been established. CRKL is involved in integrin signaling and at least partially linked to the cytoskeleton.
CRKL is a unique adapter protein that can link various signaling molecules in normal and leukemic cells. Thus far, identified CRKL SH3 domain binding proteins have enzymatic function and the CRKL SH2 domain can interact with various unrelated molecules. This suggests that CRKL may play a role in several different signaling pathways. It is possible that the biological functions of CRKL may also vary widely in different cells. Since CRKL has a high homology to CRK, it will be of special interest to compare the differences in tyrosine phosphorylation and potential signaling properties of these family members. To gain insight into CRKL function, CRKL gene disruption may be useful. Finally, the role of CRKL in leukemic transformation, especially CML, is beginning to be defined and needs to be explored further.
